Plaintiff:
Bristol-Myers Squibb Company
Defendants:
Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories Inc.
Case Number:
3:12-cv-07800
Date Filed:
December 21, 2012
Court:New Jersey District Court
Patents-in-Suit: US6670384, US7022330 and RE41393
Patent
Number
Current
Assignee[*]
|
Issued Date
|
Expiration Date[†]
|
Title
|
|
Dec 30, 2003
|
Jan 23, 2022
|
Methods of
administering epothilone analogs for the treatment of cancer
|
|
Apr 04, 2006
|
Jan 17, 2022
|
Parenteral
formulation for epothilone analogs
|
Bristol-Myers
Squibb
|
Jun 22, 2010
|
Jan 17, 2022
|
Treatment of
refractory tumors using epothilone derivatives
|
Table
information sourced from Maxval’s Assignment Database.
The
‘384 and ‘330 patents
relate to methods of
administration for parenteral and oral compositions of certain epothilone
analogs that are characterized by enhanced clinical efficacy, while the ‘393 patent relates to the use of certain
potent epothilone analogs in the treatment of tumors that have demonstrated
resistance to therapy with other chemotherapeutic agents.
About the Parties:
Bristol-Myers
Squibb (BMS) is a biopharmaceutical company engaged
in the discovery, development, licensing, manufacturing, marketing,
distribution, and sale of biopharmaceutical products that help patients prevail
over serious diseases worldwide. The company sells its products to wholesalers,
as well as directly to distributors, retailers, hospitals, clinics, government
agencies, and pharmacies. The company was formerly known as Bristol-Myers
Company and changed its name to Bristol-Myers Squibb Company in 1989.
Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New
York, New York.
Dr. Reddy’s Laboratories (DRL) is an integrated pharmaceutical company
focused on providing medicines through its three business segments: Global
Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment
and Proprietary Products segment. Dr. Reddy's manufactures and markets a wide
range of pharmaceuticals in India and overseas.
As in Complaint:
BMS
is the current holder[‡] of the New Drug Application (NDA) no. 022-065
for Ixempra® Kit (source: Maxval’s Patent
Marker) that is approved by FDA.
Ixempra Kit (see Fig. 1) delivers a microtubule inhibitor and is indicated for
both mono therapy and combination therapy breast cancer treatment. BMS alleges
that DRL seeks FDA approval to market a generic
version of Ixempra® Kit with the
Abbreviated New Drug Application (ANDA) no. 20-4303 that infringes the above
patents.
Fig. 1
Other Cases Filed:
Other
cases filed by Bristol-Myers Squibb are as follows:
Defendant
|
Case Number
|
Date Filed
|
Status
|
Sandoz
|
06/21/2012
|
Pending
|
|
Apotex
|
11/23/2011
11/08/2010
03/08/2005
|
Closed
Pending
Closed
|
|
Teva
Pharmaceuticals
|
09/22/2010
04/01/2010
03/11/2010
12/02/2009
|
Pending
Pending
Pending
Pending
|
|
Sicor Pharmacutical
|
03/08/2005
|
Closed
|
If you are interested in knowing more about the cases filed,
please contact us.
To get alerts on cases filed, subscribe to our Litigation Alerts.
[*]MaxVal offers Patent
Assignment Alert service where subscribers receive email alerts when
assignments relating to target applications, patents or entities of interest
are recorded.
[†]Expected
expiration date. Patent Term
Estimator is a free web-based tool that automatically calculates patent terms and
expiration dates for U.S. utility patents.
[‡]Patent Marker provides an online environment for patentees to
virtually mark products and search for patent related information.
No comments:
Post a Comment